Pharmaceutical intelligence for CMG PHARM CO LTD with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

RegulatoryAugust 6, 2026

FDA Submission Update for MEZOFY (Aripiprazole) by CMG PHARM CO LTD

CMG PHARM CO LTD has submitted a supplemental application for MEZOFY (Aripiprazole) under NDA211448.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(1)

RegulatoryAugust 6, 2026

FDA Submission Update for MEZOFY (Aripiprazole) by CMG PHARM CO LTD

CMG PHARM CO LTD has submitted a supplemental application for MEZOFY (Aripiprazole) under NDA211448.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

MEZOFY →

Therapeutic areas

Antipsychotic →

Neurology →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.